Imigran-T (Sumatriptan Succinate)

Sumatriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerves, causing vasoconstriction and blocking the release of inflammatory neuropeptides, which together interrupt the migraine pain cascade.

The appropriate dose of Imigran‑T is determined by the prescribing healthcare professional based on the patient’s clinical condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of sumatriptan in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Imigran‑T product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imigran‑T belongs to the triptan class, which is generally more effective for moderate to severe migraine attacks than simple analgesics. Compared with newer CGRP antagonists, triptans act via serotonin receptors and have a well‑established efficacy profile, though they carry specific cardiovascular considerations.

Imigran‑T should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date.

Imigran‑T is taken orally with a glass of water. It is usually administered at the first sign of a migraine attack and may be repeated after two hours if needed, but no more than the maximum daily dose prescribed by the healthcare professional.

Serious risks include coronary vasospasm, which can cause chest pain, and serotonin syndrome when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience severe chest discomfort, rapid heart rate, or signs of an allergic reaction.

Imigran‑T is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to sumatriptan or any excipients. It should also be avoided in individuals taking other triptans or ergotamine-containing medications.